News
The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback